Abstract
Advanced glycation end product (AGE) and receptor (RAGE) axis play a central role in the pathogenesis of diabetic vascular complications. Since peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists have been reported to reduce RAGE gene expression and subsequently suppress the downstream signalings in human umbilical vein endothelial cells (HUVECs), we examined here whether telmisartan, a unique angiotensin II type 1 receptor blocker with PPAR-γ agonistic activity, could inhibit the AGE-induced up-regulation of plasminogen activator inhibitor-1 (PAI-1) mRNA levels in HUVECs by suppressing RAGE gene expression. Telmisartan completely blocked the AGE-induced RAGE gene up-regulation in HUVECs, which was partly prevented by GW9662, an inhibitor of PPAR-γ. Further, telmisartan was also found to inhibit up-regulation of mRNA levels for PAI-1 in AGE-exposed HUVECs, which was completely prevented by GW9662. These results suggest that telmisartan inhibits the AGE-induced PAI-1 gene induction in HUVECs by down-regulating RAGE expression via PPAR-γ activation. Our present study suggests that telmisartan works as an anti-thrombogenic agent against AGEs, which may play a protective role against vascular complications in diabetes.
Keywords: AGEs, RAGE, Telmisartan, PAI-1, PPAR-γ
Letters in Drug Design & Discovery
Title: Telmisartan Blocks Advanced Glycation End Product (AGE)-Induced Plasminogen Activator Inhibitor-1 (PAI-1) Gene Expression in Endothelial Cells via Activation of Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ )
Volume: 5 Issue: 8
Author(s): Takanori Matsui, Kazuo Nakamura, Masayoshi Takeuchi and Sho-ichi Yamagishi
Affiliation:
Keywords: AGEs, RAGE, Telmisartan, PAI-1, PPAR-γ
Abstract: Advanced glycation end product (AGE) and receptor (RAGE) axis play a central role in the pathogenesis of diabetic vascular complications. Since peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists have been reported to reduce RAGE gene expression and subsequently suppress the downstream signalings in human umbilical vein endothelial cells (HUVECs), we examined here whether telmisartan, a unique angiotensin II type 1 receptor blocker with PPAR-γ agonistic activity, could inhibit the AGE-induced up-regulation of plasminogen activator inhibitor-1 (PAI-1) mRNA levels in HUVECs by suppressing RAGE gene expression. Telmisartan completely blocked the AGE-induced RAGE gene up-regulation in HUVECs, which was partly prevented by GW9662, an inhibitor of PPAR-γ. Further, telmisartan was also found to inhibit up-regulation of mRNA levels for PAI-1 in AGE-exposed HUVECs, which was completely prevented by GW9662. These results suggest that telmisartan inhibits the AGE-induced PAI-1 gene induction in HUVECs by down-regulating RAGE expression via PPAR-γ activation. Our present study suggests that telmisartan works as an anti-thrombogenic agent against AGEs, which may play a protective role against vascular complications in diabetes.
Export Options
About this article
Cite this article as:
Matsui Takanori, Nakamura Kazuo, Takeuchi Masayoshi and Yamagishi Sho-ichi, Telmisartan Blocks Advanced Glycation End Product (AGE)-Induced Plasminogen Activator Inhibitor-1 (PAI-1) Gene Expression in Endothelial Cells via Activation of Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ ), Letters in Drug Design & Discovery 2008; 5 (8) . https://dx.doi.org/10.2174/157018008786898590
DOI https://dx.doi.org/10.2174/157018008786898590 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Coronary Artery Disease and Endothelial Dysfunction: Novel Diagnostic and Therapeutic Approaches
Current Medicinal Chemistry Natural Products as Anti-glycation Agents: Possible Therapeutic Potential for Diabetic Complications
Current Diabetes Reviews Beta-Blockers in Children with Congenital Heart Disease Before a Corrective Procedure
Reviews on Recent Clinical Trials Malaria and artemisinin derivatives: an updated review
Mini-Reviews in Medicinal Chemistry Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry Dietary Lutein and Zeaxanthin in the Prevention of Age-Related Macular Degeneration in the Elderly
Current Nutrition & Food Science Diabetes, the Renin-Angiotensin System and Heart Disease
Current Vascular Pharmacology Fc-Independent Phagocytosis: Implications for Intravenous IgG Therapy in Immune Thrombocytopenia
Cardiovascular & Hematological Disorders-Drug Targets Pharmacological Properties of Physical Exercise in The Elderly
Current Pharmaceutical Design Effect of Androgenic and Antiandrogenic Acting Compounds in Macrophage Accumulation and Cell Replication in the Aorta of Oophorectomized Hypercholesterolemic Rabbits
Vascular Disease Prevention (Discontinued) Anti Diabetic Effect of Cherries in Alloxan Induced Diabetic Rats
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Clinical Utility of Biomarkers in Premature Atherosclerosis
Current Medicinal Chemistry Editorial (Thematic Issue: Current Therapeutic Options in Cardiomyopathies)
Current Pharmaceutical Design Molecular Structural Characteristics of Estrogen Receptor Modulators as Determinants of Estrogen Receptor Selectivity
Mini-Reviews in Medicinal Chemistry Myths and Facts Concerning the Use of Statins in Very Old Patients
Cardiovascular & Hematological Disorders-Drug Targets Contemporary Overview on Clinical Trials and Future Prospects of Hepato-protective Herbal Medicines
Reviews on Recent Clinical Trials Vascular C-Reactive Protein in the Pathogenesis of Coronary Artery Disease:Role of Vascular Inflammation and Oxidative Stress
Cardiovascular & Hematological Disorders-Drug Targets Vitamin D3, D2 and Arterial Wall Properties in Coronary Artery Disease
Current Pharmaceutical Design Application of Pharmacogenomic Approaches in the Study of Drug Response in Complex Diseases
Current Pharmacogenomics Calcium Sensitizers in Cardiac Surgery: Who, When, How and Why?
Current Vascular Pharmacology